Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure.
about
Potential role of dipeptidyl peptidase IV in the pathophysiology of heart failureOmega-3 Fatty Acids and FFAR4Congestive heart failure and diabetes mellitus: balancing glycemic control with heart failure improvementGLP-1 and cardioprotection: from bench to bedsideDPP4 deficiency preserved cardiac function in abdominal aortic banding ratsCardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetesA protocol for a randomised, double-blind, placebo-controlled study of the effect of LIraglutide on left VEntricular function in chronic heart failure patients with and without type 2 diabetes (The LIVE Study)Glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1: Incretin actions beyond the pancreas.Cardiovascular and hemodynamic effects of glucagon-like peptide-1.Cardioprotective effects of lixisenatide in rat myocardial ischemia-reperfusion injury studies.Association of antidiabetic medications targeting the glucagon-like peptide 1 pathway and heart failure events in patients with diabetes.Selective targeting of glucagon-like peptide-1 signalling as a novel therapeutic approach for cardiovascular disease in diabetesThe cardiovascular effects of glucagon-like peptide-1 receptor agonists: a trial sequential analysis of randomized controlled trials.Saxagliptin restores vascular mitochondrial exercise response in the Goto-Kakizaki ratExendin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrixPostprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretinsCardioprotection Resulting from Glucagon-Like Peptide-1 Administration Involves Shifting Metabolic Substrate Utilization to Increase Energy Efficiency in the Rat HeartMetabolic Syndrome Abolishes Glucagon-Like Peptide 1 Receptor Agonist Stimulation of SERCA in Coronary Smooth MuscleGLP-1 receptor agonists: Nonglycemic clinical effects in weight loss and beyond.Cardiovascular biology of the incretin system.Glucagon-like peptide-1 protects cardiomyocytes from advanced oxidation protein product-induced apoptosis via the PI3K/Akt/Bad signaling pathway.Metabolically-inactive glucagon-like peptide-1(9-36)amide confers selective protective actions against post-myocardial infarction remodelling.Exendin-4 induces myocardial protection through MKK3 and Akt-1 in infarcted heartsSaxagliptin Improves Glucose Tolerance but not Survival in a Murine Model of Dilated CardiomyopathyImpaired cardiometabolic responses to glucagon-like peptide 1 in obesity and type 2 diabetes mellitusNovel fusion of GLP-1 with a domain antibody to serum albumin prolongs protection against myocardial ischemia/reperfusion injury in the ratAdenosine A2A receptor agonist prevents cardiac remodeling and dysfunction in spontaneously hypertensive male rats after myocardial infarction.Cardiovascular effects of incretin-based therapies.Potential cardiovascular effects of incretin-based therapies.Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1.The therapeutic potential of GPR43: a novel role in modulating metabolic health.GLP-1 receptor agonists: effects on cardiovascular risk reduction.Direct cardiovascular effects of glucagon like peptide-1.Impact of glucagon-like peptide-1 on myocardial glucose metabolism revisited.Newest additions to heart failure treatment.Incretin-related drug therapy in heart failure.Interdisciplinary approach to compensation of hypoglycemia in diabetic patients with chronic heart failure.The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE -/- mice fed a western diet.Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure.Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes.
P2860
Q26829634-E4F2C2E2-F1FB-4930-BF90-5BEEADFDF713Q27000272-1123D6D9-7DF6-4B7B-B4B0-5D3918DFB561Q27003819-02C8A2CF-4855-4DD6-A2B6-93C6B084F67CQ27024984-6DEF10BD-3552-4585-A9A5-FFF577E34B16Q28538591-0A6090E2-7BE2-4A2C-87AD-AD13DF439989Q28741419-9B290329-632E-4F8E-91A7-92B9D4B39AAAQ30437335-2A336C48-0DC0-4D4B-9922-332E46331908Q33603384-2D5D8BEE-6DF4-4D20-A188-903C56C627BEQ33993725-24885CF4-9402-4F6B-B9F5-B7D88445F27FQ34640125-85A6F555-10CF-43DE-AD1F-9C0C3C99EB87Q34771795-52A75E4A-505C-4867-BCD8-19985762313FQ34994502-CD2900F8-BB04-4220-867C-341CA247ED04Q35017639-F286DF50-31C6-4620-A1F7-804ED5DA2F17Q35060739-495DB37C-2A20-4226-BFDD-CD96CD334AB9Q35132702-7A321C90-A689-4A72-8A02-1BFAA57E2368Q35249760-5D535C93-871C-4803-ACA5-1B74C17D5536Q35670896-55E3AF08-7850-4C3A-920E-A437C4C898F7Q35973848-A01A01CB-D862-4840-9FB0-D8AE641AA33EQ36406821-CF3E69B3-E97D-485F-B60C-6540C5448FD0Q36484283-E627EBEA-1ECE-45D4-957C-346B78197F64Q36520207-44BA5E24-E165-4DC6-8782-9C63BD5DBE8FQ36800422-937BEFB0-E532-4FBE-B712-573F3EE166CCQ36895565-607401B5-24A1-4D73-BAF8-41AB7A65B1D5Q36939647-827C35CE-17FA-419E-9467-20E1BF8BCDFCQ37065219-0E96644F-8EC8-4727-8D33-8DA27EAAF8C0Q37367934-50209082-1463-4F8F-A88F-34D61C6EE0A5Q37693771-CE581DA7-D628-4AC6-902E-8F73262E5009Q37977336-E621104E-D672-4297-8E08-14B3A094C35EQ37990619-3A3C6856-F15A-4F09-983D-6D0ED777D7D5Q38066566-8179CE11-E50C-442E-8030-E8427145AE58Q38121495-258BEF95-7EBB-4858-AC60-A34238F11A31Q38122396-D8A5DE9C-BF21-4305-A7DF-B0F138E3CC16Q38132470-121C7493-50D6-41A8-9D22-A1C2EE56BE02Q38218639-1F3E92D5-DF9F-41FA-98D8-9520D31DE9D1Q38225739-D0137CD4-9B03-4381-A7C7-B54AD1D658F4Q38260853-2C4A81A5-47F4-453A-BAA5-CB86B4DFA7BAQ38604382-AC5B385B-7FE1-4124-961F-35A42DA86683Q38730067-957D1578-9666-4277-A2BC-825E986E4855Q38787227-A3601C4C-BB67-4616-A9CF-2A4DE12142D0Q39600857-D5EE3CC6-8B9D-4277-B50C-4E6040CCE241
P2860
Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Glucagon-like peptide-1 and th ...... ts with chronic heart failure.
@en
type
label
Glucagon-like peptide-1 and th ...... ts with chronic heart failure.
@en
prefLabel
Glucagon-like peptide-1 and th ...... ts with chronic heart failure.
@en
P2093
P2860
P356
P1476
Glucagon-like peptide-1 and th ...... ts with chronic heart failure.
@en
P2093
Alain Baron
Anatoly Broyde
Christen Anderson
Clara Polizzi
David G Parkes
Rayne Fernandez
P2860
P2888
P356
10.1186/1475-2840-9-76
P407
P577
2010-11-16T00:00:00Z
P5875
P6179
1014654111